Cresco Labs Inc. (OTCMKTS:CRLBF - Free Report) - Ventum Cap Mkts issued their FY2026 earnings estimates for shares of Cresco Labs in a report issued on Monday, November 11th. Ventum Cap Mkts analyst A. Semple expects that the company will post earnings per share of ($0.06) for the year. Ventum Cap Mkts has a "Strong-Buy" rating on the stock. The consensus estimate for Cresco Labs' current full-year earnings is ($0.19) per share.
Other equities research analysts also recently issued research reports about the stock. Roth Capital upgraded shares of Cresco Labs to a "strong-buy" rating in a research report on Sunday. Needham & Company LLC reaffirmed a "hold" rating on shares of Cresco Labs in a research note on Monday, August 12th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $2.50.
Read Our Latest Analysis on Cresco Labs
Cresco Labs Stock Performance
OTCMKTS CRLBF traded up $0.22 on Wednesday, hitting $1.26. 1,385,855 shares of the company were exchanged, compared to its average volume of 907,402. Cresco Labs has a twelve month low of $1.02 and a twelve month high of $2.65. The company has a debt-to-equity ratio of 1.76, a current ratio of 2.00 and a quick ratio of 1.30. The company's 50 day moving average price is $1.59 and its 200-day moving average price is $1.71.
Cresco Labs Company Profile
(
Get Free Report)
Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Read More
Before you consider Cresco Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cresco Labs wasn't on the list.
While Cresco Labs currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
